Orforglipron vs Semaglutide
One is an approved weekly injection with a cardiovascular outcomes trial behind it; the other is an investigational once-daily pill whose case rests on access, not peak efficacy.
Orforglipron
~11% in ATTAIN-1; a scalable oral pill whose appeal is access, not peak efficacy. Investigational.
Full Orforglipron evidence reviewSemaglutide
Wegovy / Ozempic
~15% mean weight loss in STEP 1; the benchmark that opened modern obesity medicine.
Full Semaglutide evidence reviewSide by side
| Orforglipron | Semaglutide | |
|---|---|---|
| Marketed for | Weight loss, type-2 diabetes | Weight loss, type-2 diabetes |
| Evidence grade | Clinical data | FDA-approved |
| Family | GLP-1 / incretin | GLP-1 / incretin |
| Regulatory status | Investigational | FDA-approved |
| How it's obtained | Research-only | Rx product |
| Key human source | ATTAIN-1, NEJM 2025 | STEP 1, NEJM 2021 |
marks a row where the two differ. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
Our verdict
Semaglutide is approved, and STEP 1 plus the SELECT cardiovascular result give it by far the deeper evidence base. Orforglipron is investigational; it cannot be prescribed. On weight, semaglutide reported about 14.9% in STEP 1 against roughly 11% for orforglipron in ATTAIN-1, but those come from separate trials and were not compared directly. Orforglipron's real argument is form, a non-peptide small molecule taken as a once-daily tablet with no food or water restrictions, and it has no long-term cardiovascular or renal outcomes data yet.
Orforglipron fits if
You are tracking what a manufacturable, food-unrestricted oral GLP-1 could mean for access, and you are following the regulatory path rather than starting treatment.
Semaglutide fits if
You want a GLP-1 available now, with pivotal weight-loss trials and a dedicated cardiovascular outcomes trial behind it.